GlassScriptPhysician profile
James Brian Young
NPI 1295965119
$1,785.51
in general payments reported to CMS, 2019-2025
24 companies · $257 in 2025
The $257 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $294 · 2020: $18.49 · 2021: $211 · 2022: $379 · 2023: $151 · 2024: $475 · 2025: $257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $883.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $883.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $211.13 | 2019-2024 | Dysport |
| Regeneron Healthcare Solutions, INC. | $175.54 | 2022-2025 | Libtayo, Dupixent |
| Amgen INC. | $173.38 | 2021-2024 | Otezla, Enbrel |
| Sun Pharmaceutical Industries INC. | $170.90 | 2019-2025 | |
| Smith+Nephew, INC. | $136.73 | 2022-2023 | Grafix, Stravix |
| Celgene Corporation | $131.72 | 2019 | |
| Abbvie INC. | $128.42 | 2022-2025 | |
| Genentech USA, INC. | $116.55 | 2021-2022 | |
| Organogenesis INC. | $73.85 | 2024 | |
| Pfizer INC. | $65.33 | 2022-2025 | |
| Leo Pharma INC. | $61.81 | 2024-2025 | Adbry |
| Novartis Pharmaceuticals Corporation | $60.06 | 2019-2022 | |
| Genzyme Corporation | $57.49 | 2021-2022 | |
| Ucb, INC. | $29.13 | 2025 | Bimzelx |
| Lilly USA, LLC | $27.14 | 2024 | Taltz, Olumiant |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biowound Solutions, INC. | $26.61 | 2025 | Bio-Connekt |
| Hologic Sales and Service, LLC | $24.88 | 2023 | Omni Hysteroscope, Myosure Tissue Removal Device, Novasure |
| Dermira, INC. | $23.72 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.77 | 2024 | Spevigo |
| Incyte Corporation | $18.87 | 2023 | Opzelura |
| Janssen Biotech, INC. | $15.20 | 2024 | Tremfya, Stelara, Simponi |
| Acera Surgical, INC. | $13.76 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $13.53 | 2025 | Jublia |
| Mayne Pharma Commercial LLC | $7.99 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.